A difficult-to-treat pleuropulmonary histoplasmosis in a patient with rheumatoid arthritis in Taiwan.

Authors :: Chu WK
Wu UI
Lee TF
Cheng A
Chen KH
Lin KY
Chen YC
Source :: Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi [J Microbiol Immunol Infect] 2023 Feb; Vol. 56 (1), pp. 192-196. Date of Electronic Publication: 2022 Dec 13.
Publication Year :: 2023
Abstract: Amphotericin B and itraconazole are the primary agents for treating histoplasmosis. Newer azoles are alternatives for patients refractory to or intolerant of standard therapy. We report an 83-year-old woman with rheumatoid arthritis complicated with pleuropulmonary histoplasmosis who responded to liposomal amphotericin B, but progressed under voriconazole and posaconazole maintenance therapy.<br />Competing Interests: Declaration of competing interest All authors declare no conflict of interest.<br /> (Copyright © 2022. Published by Elsevier B.V.)

Subjects :: Female
Humans
Aged, 80 and over
Antifungal Agents therapeutic use
Taiwan
Histoplasma
Histoplasmosis complications
Histoplasmosis diagnosis
Histoplasmosis drug therapy
Arthritis, Rheumatoid complications
Arthritis, Rheumatoid drug therapy

Language :: English
ISSN :: 1995-9133
Volume :: 56
Issue :: 1
Database :: MEDLINE
Journal :: Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
Publication Type :: Academic Journal
Accession number :: 36564267
Full Text :: https://doi.org/10.1016/j.jmii.2022.12.005

Full Text Access

Tools